Personal information

Verified email addresses

Verified email domains

Nephrology
Japan

Activities

Employment (3)

Cedars-Sinai Medical Center: Los Angeles, US

2023-04 to present (Pathology and Laboratory Medicine)
Employment
Source: Self-asserted source
Suguru Saito

Tokyo Medical University Hospital: Tokyo, JP

2016-04 to present (Nephrology)
Employment
Source: Self-asserted source
Suguru Saito

Tokyo Metropolitan Police Hospital: Tokyo, JP

2019-04 to 2022-03 (Nephrology, endocrinology, diabetes and metabolism)
Employment
Source: Self-asserted source
Suguru Saito

Education and qualifications (2)

Tokyo Medical University: Tokyo, JP

2016-04 to 2020-03 | PhD
Education
Source: Self-asserted source
Suguru Saito

Tokyo Medical University: Tokyo, JP

2008-04 to 2014-03 | MD
Education
Source: Self-asserted source
Suguru Saito

Funding (1)

Treatment of renal fibrosis by short miRNA mimic

2017-04 to 2020-03 | Grant
Japan Society for the Promotion of Science (Tokyo, JP)
GRANT_NUMBER:

17K16101

Source: Self-asserted source
Suguru Saito

Works (5)

Larger degree of renal function decline in CKD is a favorable factor for the attenuation of eGFR slope worsening by SGLT2 inhibitors: a retrospective observational study.

Nephron
2024-04-01 | Journal article
Contributors: Miyaoka Y; Moriyama T; Saito S; Rinno S; Kato M; Tsujimoto R; Suzuki R; China R; Nagai M; Kanno Y
Source: Self-asserted source
Suguru Saito

EGF Receptor-dependent TLR7 Signaling in Macrophages Promotes Glomerular Injury in Crescentic Glomerulonephritis.

Laboratory investigation; a journal of technical methods and pathology
2023-05-31 | Journal article | Investigation
Contributors: Tatsumoto N; Saito S; Rifkin IR; Bonegio RG; Leal DN; Sen GC; Arditi M; Yamashita M; Suguru Saito
Source: Self-asserted source
Suguru Saito

MiR-34a induces myofibroblast differentiation from renal fibroblasts.

Clinical and experimental nephrology
2023-02-18 | Journal article | Writing - original draft, Investigation
Contributors: Saito S; Shin-ichiro Ohno; Harada Y; Kanno Y; Kuroda M; Suguru Saito
Source: Self-asserted source
Suguru Saito

Semaglutide, a newly available glucagon‐like peptide receptor agonist, shows remarkable favorable effects in hemodialysis patients with obesity and Type 2 diabetes

Therapeutic Apheresis and Dialysis
2022-02 | Journal article
Contributors: Suguru Saito; Toshiyuki Nakao
Source: check_circle
Crossref

rAAV6-mediated miR-29b delivery suppresses renal fibrosis.

Clinical and experimental nephrology
2019-09-03 | Journal article | Investigation, Writing - original draft
Contributors: Saito S; Shin-ichiro Ohno; Harada Y; Oikawa K; Fujita K; Mineo S; Gondo A; Kanno Y; Kuroda M; Suguru Saito
Source: Self-asserted source
Suguru Saito